<DOC>
	<DOCNO>NCT02166593</DOCNO>
	<brief_summary>1 . Target disease : Patients combine dyslipidemia adequately control LDL-C inadequately control triglyceride level atorvastatin monotherapy 2 . Study objective : The objective study demonstrate Pravafenix Cap . clinically superior atorvastatin evaluate percent change Non-HDL-C group 8 week treatment atorvastatin Pravafenix Cap . ( pravastatin sodium/fenofibrate ) patient adequately control LDL-C inadequately control triglyceride level atorvastatin monotherapy multicenter , randomize , double blind set . 3 . Phase design : A multicenter , double blind , randomize , active control , parallel-design , Phase 3 study 4 . Duration study : 12 month IRB approval date 5 . Duration administration : 4-week single blind run-in period plus 8-week double blind treatment period</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Safety Pravafenix Cap Verify Superiority Than Atorvastatin</brief_title>
	<detailed_description>This study Evaluate Efficacy Safety Pravastatin/Fenofibrate Complex Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level Atorvastatin Monotherapy . After administrate atorvastatin Pravafenix Cap . ( pravastatin sodium/fenofibrate ) 8 week , evaluate variation Non-HDL-C arm . Ultimatly verificaite Pravafenix Cap . ( pravastatin sodium/fenofibrate ) good effect atorvastatin .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Screening visit ( PreStudy Visit : D28 ) 1 . Men woman age ≥ 20 &lt; 80 2 . Patients high risk coronary heart disease accord NCEP ATPIII guideline Patients coronary artery disease , Patients symptomatic carotid artery disease , Patients peripheral vascular disease , Patients abdominal aneurysm , Patients diabetes mellitus , Patients 20 % 10year risk coronary heart disease , 3 . LDLC &lt; 160mg/dL screen 4 . Fasting triglyceride ( TG ) level ≥ 150mg/dL &lt; 500mg/dL screen 5 . HDLC level &lt; 40mg/dL ( Male Patient ) , &lt; 50mg/dL ( Female Patient ) 6 . Voluntary write informed consent study participation Secondary visit ( Visit 2 ( D0 ) ) 1 . LDLC &lt; 100mg/dL 4week atorvastatin runin period 2 . Fasting TG level ≥ 150mg/dL &lt; 500mg/dL 4week atorvastatin runin period 3 . HDLC level &lt; 40mg/dL ( Male Patient ) , &lt; 50mg/dL ( Female Patient ) 1 . Acute arterial disease ( history unstable angina pectoris , myocardial infarction , acute coronary syndrome , transient ischemic attack , cerebrovascular disease , coronary bypass , coronary artery disease within 3 month prior study participation ) 2 . Revascularzation procedure aortic aneurysm operation within 6 month prior study participation 3 . Myopathy , history rhabdomyolysis myopathy due statin fibrates , elevate CK level ≥ 5 x upper limit normal ( ULN ) previous statin treatment 4 . Acute chronic pancreatitis due hypertriglyceridemia 5 . Cardiovascular , hepatic , neurological , endocrine , serious systemic disease may affect study conduct interpretation study result 6 . Known positive serum test human immunodeficiency virus ( HIV ) Antibody I II 7 . Diagnosis cancer within past 2 year ( except successfully treat basal cell carcinoma squamous cell carcinoma ) 8 . Patients treat prohibited concomitant medication study period treatment prohibit concomitant medication consider inevitable ( systemic inhalant corticosteroid may allow study provide treatment maintain dose . ) 9 . Administration administer periodic sex hormone therapies oral contraceptive within 2 month prior screen visit study participation 10 . Moderate severe renal impairment ( GFR &lt; 60ml/min ) screen 11 . Severe hepatic impairment AST/ALT level &gt; 3 x ULN screening ( biliary cirrhosis , active liver disease , continue increase transaminase unknown cause ( &gt; 3 x ULN ) , etc . ) 12 . Uncontrolled hypothyroidism 13 . Uncontrolled diabetes mellitus ( HbA1c &gt; 8.5 % ) 14 . Hyperlipidemia Class I , IIa , IV , V 15 . Requiring insulin treatment diabetes mellitus 16 . Allergies hypersensitivity reaction study drug 17 . Patients know , suspected history drug alcohol abuse within past 2 year 18 . Confirmed pregnant lactate woman screen 19 . Women childbearing potential screening planning become pregnant study . Women childbearing age undergo surgical sterilization may participate study pregnancy test determine negative maintain effective contraceptive method throughout study period . Periodic abstinence ( e.g. , calendar method , ovulation method , symptothermal method , postovulation method ) self control consider acceptable contraceptive method , use hormonal contraceptive allow . 20 . Having participate another clinical trial within 1 month prior screen 21 . History photoallergic phototoxic reaction treatment fibrates ketoprofen 22 . Biliary disease 23 . Interstitial pulmonary disease 24 . Other patient consider principal investigator subinvestigator inappropriate study participation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>